Important update from the GAIA CLL13 Trial com... - CLL Support
Important update from the GAIA CLL13 Trial comparing venetoclax combinations with chemoimmunotherapy for first-line CLL
You need to be a member of this community to see this post.
Read more about...
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Younger, Fit Patients With CLL: Goal Remains Undetectable Minimal Residual Disease and Time-Limited Therapy
This article looks at the interim analysis of E1912, a U.S. randomized phase III trial comparing...
Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada
* VENCLEXTA® (venetoclax) plus obinutuzumab is the first chemotherapy-free,
fixed-duration...
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
From the New England Journal of Medicine 10th December 2023
"The CLL treatment landscape has...
UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today
Probably one of the best news stories that we have been able to announce in many years for patients...
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
From Blood Cancer Journal 29th April 2021
Four strategies have been tested in recent years...
Related Posts
- Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL
- NICE Recommends Acalabrutinib for treating CLL for certain groups
Breaking news form ASH conference: looks like Ibrutinib May be better than FCR for some patients
Ibrutinib V Venetoclax + Rituximab
